<p>吉利德科学公司（NASDAQ:GILD - 获取免费报告）在 11 月份的空头头寸显著增长。截至 11 月 30 日，空头头寸总计 2341 万股，比 11 月 15 日的 1806 万股增长了 29.6%。目前，公司股票的 1.9% 被卖空。根据 684 万股的平均日交易量，空头头寸比率目前为 3.4 天。</p>
<p>获取 <strong>吉利德科学</strong> 的提醒：</p>
<h2>内部买卖</h2>
<ul>
<li>吉利德股票飙升：是什么推动了这一势头？</li>
</ul>
<p>在相关消息中，首席财务官安德鲁·D·迪金森于 11 月 29 日星期五出售了 248,645 股公司的股票，交易平均价格为 92.76 美元，总价值为 23,064,310.20 美元。交易完成后，首席财务官现在持有 138,919 股公司股票，价值为 12,886,126.44 美元。此次交易使其持股减少了 64.16%。该出售在向 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士梅尔达德·帕尔西于 11 月 27 日星期三出售了 164,211 股公司的股票，股票的平均售价为 91.92 美元，总交易额为 15,094,275.12 美元。交易完成后，该内部人士现在直接持有 80,801 股公司股票，价值为 7,427,227.92 美元。这笔交易使其持股减少了 67.02%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 447,234 股公司股票，价值为 41,288,086 美元。公司内部人士持有公司股票的 0.16%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对该股票的持有。Exome Asset Management LLC 在第三季度新购入了吉利德科学的股份，价值约 419.2 万美元。Brass Tax Wealth Management Inc.在第三季度新购入了吉利德科学的股份，价值约 24.2 万美元。Garden State Investment Advisory Services LLC 在第三季度新购入了吉利德科学的股份，价值约 22.1 万美元。富兰克林资源公司在第三季度将其在吉利德科学的持股增加了 22.8%。富兰克林资源公司目前持有 2241354 股生物制药公司的股票，价值为 1.90611 亿美元，此前在上个季度又购买了 416,379 股。最后，Tri Ri Asset Management Corp 在第三季度新购入了吉利德科学的股份，价值约 338 万美元。机构投资者和对冲基金持有公司股票的 83.67%。</p>
<h2>吉利德科学价格表现</h2>
<ul>
<li>生物技术繁荣在即？现在值得关注的关键股票和 ETF</li>
</ul>
<p>吉利德科学的股票在周五的交易中上涨了 0.24 美元，达到 91.86 美元。该股票的交易量为 7,515,462 股，而其平均交易量为 7,068,425 股。该股票的 50 日移动平均线为 89.96 美元，200 日移动平均线为 79.55 美元。该公司的市值为 1144.8 亿美元，市盈率为 1,020.61，市盈增长比率为 2.38，贝塔值为 0.18。吉利德科学的 12 个月低点为 62.07 美元，12 个月高点为 98.90 美元。公司的流动比率为 1.26，速动比率为 1.10，债务与股本比率为 1.24。</p>
<p>吉利德科学（NASDAQ:GILD - 获取免费报告）最近一次发布季度财报是在 11 月 6 日星期三。这家生物制药公司报告本季度每股收益为 2.02 美元，超出分析师一致预期的 1.58 美元，超出幅度为 0.44 美元。该公司本季度的收入为 75.5 亿美元，而一致预期为 70.1 亿美元。吉利德科学的净利润率为 0.45%，股本回报率为 29.00%。与去年同期相比，公司收入增长了 7.0%。在去年同期，该公司每股收益为 2.29 美元。股票分析师预计吉利德科学在本财年的每股收益将达到 4.35 美元。</p>
<h2>吉利德科学分红公告</h2>
<ul>
<li>积极消息推动这家癌症药物制造商的股票上涨</li>
</ul>
<p>该公司最近宣布了季度分红，将于 12 月 30 日星期一支付。12 月 13 日星期五的登记投资者将获得每股 0.77 美元的分红。除息日期为 12 月 13 日星期五。这代表着年化分红为 3.08 美元，分红收益率为 3.35%。吉利德科学的分红支付比率（DPR）目前为 3,422.22%。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 GILD 股票发布了报告。桑福德·C·伯恩斯坦在 10 月 17 日星期四开始对吉利德科学进行覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 105.00 美元的目标价。派珀·桑德勒在 11 月 7 日星期四将吉利德科学的目标价从 95.00 美元上调至 105.00 美元，并给予该股票 “增持” 评级。罗伯特·W·贝尔德在 11 月 7 日星期四将吉利德科学的目标价从 80.00 美元上调至 95.00 美元，并给予该股票 “中性” 评级。Needham &amp; Company LLC 在 11 月 7 日星期四重申了对吉利德科学股票的 “持有” 评级。最后，Leerink Partners 在 10 月 21 日星期一将吉利德科学的评级从 “市场表现” 上调至 “跑赢大盘”，并将该股票的目标价从 74.00 美元上调至 96.00 美元。十二位分析师对该股票给予了持有评级，十二位给予了买入评级，四位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 96.43 美元。</p>
<p><strong>获取我们对 GILD 的最新分析</strong></p>
<h2>关于吉利德科学</h2>
<p>（获取免费报告）</p>
<p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>Dave &amp; Buster’s：是时候再次投资这只股票了吗？</li>
<li>安静期到期的解释</li>
<li>为什么好时股票在被拒绝收购后仍有上涨空间</li>
<li>什么是国债？</li>
<li>德州仪器：仍在交付的老牌科技巨头</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<p>→ 比特币（来自 Awesomely, LLC）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg3NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg3NQ"/></p>
<h2>你现在应该投资 1,000 美元在吉利德科学吗？</h2>
<p>在考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

<p>吉利德科学（NASDAQ:GILD）在短期空头头寸方面经历了显著增长，截至 11 月 30 日，短期空头头寸增加了 29.6%，达到 23,410,000 股。这占公司已售空股票的 1.9%，覆盖天数比率为 3.4 天。此外，公司的内部人士在过去 90 天内出售了 447,234 股。吉利德的股价达到了 76.24 美元，市值为 480 亿美元，市盈率为 1,020.61。公司还宣布每股季度股息为 0.77 美元，将于 12 月 30 日支付</p>

<p>Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 23,410,000 shares, a growth of 29.6% from the November 15th total of 18,060,000 shares. Currently, 1.9% of the company's stock are sold short. Based on an average daily trading volume, of 6,840,000 shares, the short-interest ratio is presently 3.4 days.</p>
<div class="lb-trans"><p>吉利德科学公司（NASDAQ:GILD - 获取免费报告）在 11 月份的空头头寸显著增长。截至 11 月 30 日，空头头寸总计 2341 万股，比 11 月 15 日的 1806 万股增长了 29.6%。目前，公司股票的 1.9% 被卖空。根据 684 万股的平均日交易量，空头头寸比率目前为 3.4 天。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>吉利德科学</strong> 的提醒：</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Gilead’s Stock Surge: What’s Fueling the Momentum?</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德股票飙升：是什么推动了这一势头？</li>
</ul>
</div><p>In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 447,234 shares of company stock valued at $41,288,086 over the last 90 days. Corporate insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官安德鲁·D·迪金森于 11 月 29 日星期五出售了 248,645 股公司的股票，交易平均价格为 92.76 美元，总价值为 23,064,310.20 美元。交易完成后，首席财务官现在持有 138,919 股公司股票，价值为 12,886,126.44 美元。此次交易使其持股减少了 64.16%。该出售在向 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士梅尔达德·帕尔西于 11 月 27 日星期三出售了 164,211 股公司的股票，股票的平均售价为 91.92 美元，总交易额为 15,094,275.12 美元。交易完成后，该内部人士现在直接持有 80,801 股公司股票，价值为 7,427,227.92 美元。这笔交易使其持股减少了 67.02%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 447,234 股公司股票，价值为 41,288,086 美元。公司内部人士持有公司股票的 0.16%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Exome Asset Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $4,192,000. Brass Tax Wealth Management Inc. acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $242,000. Garden State Investment Advisory Services LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $221,000. Franklin Resources Inc. raised its position in shares of Gilead Sciences by 22.8% during the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company's stock worth $190,611,000 after purchasing an additional 416,379 shares during the last quarter. Finally, Tri Ri Asset Management Corp acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $3,380,000. Institutional investors and hedge funds own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。Exome Asset Management LLC 在第三季度新购入了吉利德科学的股份，价值约 419.2 万美元。Brass Tax Wealth Management Inc.在第三季度新购入了吉利德科学的股份，价值约 24.2 万美元。Garden State Investment Advisory Services LLC 在第三季度新购入了吉利德科学的股份，价值约 22.1 万美元。富兰克林资源公司在第三季度将其在吉利德科学的持股增加了 22.8%。富兰克林资源公司目前持有 2241354 股生物制药公司的股票，价值为 1.90611 亿美元，此前在上个季度又购买了 416,379 股。最后，Tri Ri Asset Management Corp 在第三季度新购入了吉利德科学的股份，价值约 338 万美元。机构投资者和对冲基金持有公司股票的 83.67%。</p>
</div><h2>Gilead Sciences Price Performance</h2>
<div class="lb-trans"><h2>吉利德科学价格表现</h2>
</div><ul>
<li>Biotech Boom Ahead? Key Stocks and ETFs to Watch Now</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术繁荣在即？现在值得关注的关键股票和 ETF</li>
</ul>
</div><p>Shares of Gilead Sciences stock traded up $0.24 during trading hours on Friday, reaching $91.86. The stock had a trading volume of 7,515,462 shares, compared to its average volume of 7,068,425. The stock's 50 day moving average is $89.96 and its 200 day moving average is $79.55. The firm has a market capitalization of $114.48 billion, a PE ratio of 1,020.61, a PEG ratio of 2.38 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.</p>
<div class="lb-trans"><p>吉利德科学的股票在周五的交易中上涨了 0.24 美元，达到 91.86 美元。该股票的交易量为 7,515,462 股，而其平均交易量为 7,068,425 股。该股票的 50 日移动平均线为 89.96 美元，200 日移动平均线为 79.55 美元。该公司的市值为 1144.8 亿美元，市盈率为 1,020.61，市盈增长比率为 2.38，贝塔值为 0.18。吉利德科学的 12 个月低点为 62.07 美元，12 个月高点为 98.90 美元。公司的流动比率为 1.26，速动比率为 1.10，债务与股本比率为 1.24。</p>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Equities analysts expect that Gilead Sciences will post 4.35 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）最近一次发布季度财报是在 11 月 6 日星期三。这家生物制药公司报告本季度每股收益为 2.02 美元，超出分析师一致预期的 1.58 美元，超出幅度为 0.44 美元。该公司本季度的收入为 75.5 亿美元，而一致预期为 70.1 亿美元。吉利德科学的净利润率为 0.45%，股本回报率为 29.00%。与去年同期相比，公司收入增长了 7.0%。在去年同期，该公司每股收益为 2.29 美元。股票分析师预计吉利德科学在本财年的每股收益将达到 4.35 美元。</p>
</div><h2>Gilead Sciences Dividend Announcement</h2>
<div class="lb-trans"><h2>吉利德科学分红公告</h2>
</div><ul>
<li>Positive News is Driving This Cancer Drug Maker’s Stock Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>积极消息推动这家癌症药物制造商的股票上涨</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，将于 12 月 30 日星期一支付。12 月 13 日星期五的登记投资者将获得每股 0.77 美元的分红。除息日期为 12 月 13 日星期五。这代表着年化分红为 3.08 美元，分红收益率为 3.35%。吉利德科学的分红支付比率（DPR）目前为 3,422.22%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently issued reports on GILD shares. Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an &#34;outperform&#34; rating and a $105.00 price target on the stock. Piper Sandler upped their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, November 7th. Robert W. Baird upped their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 7th. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Finally, Leerink Partners raised Gilead Sciences from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Twelve analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $96.43.</p>
<div class="lb-trans"><p>一些股票分析师最近对 GILD 股票发布了报告。桑福德·C·伯恩斯坦在 10 月 17 日星期四开始对吉利德科学进行覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 105.00 美元的目标价。派珀·桑德勒在 11 月 7 日星期四将吉利德科学的目标价从 95.00 美元上调至 105.00 美元，并给予该股票 “增持” 评级。罗伯特·W·贝尔德在 11 月 7 日星期四将吉利德科学的目标价从 80.00 美元上调至 95.00 美元，并给予该股票 “中性” 评级。Needham &amp; Company LLC 在 11 月 7 日星期四重申了对吉利德科学股票的 “持有” 评级。最后，Leerink Partners 在 10 月 21 日星期一将吉利德科学的评级从 “市场表现” 上调至 “跑赢大盘”，并将该股票的目标价从 74.00 美元上调至 96.00 美元。十二位分析师对该股票给予了持有评级，十二位给予了买入评级，四位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 96.43 美元。</p>
</div><p><strong>Get Our Latest Analysis on GILD</strong></p>
<div class="lb-trans"><p><strong>获取我们对 GILD 的最新分析</strong></p>
</div><h2>About Gilead Sciences</h2>
<div class="lb-trans"><h2>关于吉利德科学</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Dave &amp; Buster’s: Is It Time to Make Another Play on This Stock?</li>
<li>Quiet Period Expirations Explained</li>
<li>Why Hershey Stock Has More Room to Run Despite Takeover Rejection</li>
<li>What Are Treasury Bonds?</li>
<li>Texas Instruments: The Old-School Tech Titan Still Delivering</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>Dave &amp; Buster’s：是时候再次投资这只股票了吗？</li>
<li>安静期到期的解释</li>
<li>为什么好时股票在被拒绝收购后仍有上涨空间</li>
<li>什么是国债？</li>
<li>德州仪器：仍在交付的老牌科技巨头</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><p>→ BITCOIN (From Awesomely, LLC)(Ad)</p>
<div class="lb-trans"><p>→ 比特币（来自 Awesomely, LLC）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg3NQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10875&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Gilead Sciences right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

吉利德科学公司（NASDAQ:GILD）的空头头寸大幅增加